Primary prophylaxis of cryptococcal disease with fluconazole in HIV-positive Ugandan adults: a double-blind, randomised, placebo-controlled trial

被引:46
|
作者
Parkes-Ratanshi, Rosalind [1 ,2 ,3 ]
Wakeham, Katie [1 ,2 ]
Levin, Jonathan [1 ,4 ]
Namusoke, Deodata [5 ]
Whitworth, James [6 ]
Coutinho, Alex [5 ,7 ]
Mugisha, Nathan Kenya [8 ]
Grosskurth, Heiner [1 ,9 ]
Kamali, Anatoli [1 ]
Lalloo, David G. [2 ]
机构
[1] UVRI, MRC, Uganda Res Unit AIDS, Entebbe, Uganda
[2] Univ Liverpool, Liverpool Sch Trop Med, Liverpool L3 5QA, Merseyside, England
[3] Imperial Coll Sci & Technol, Dept Infect Dis, London, England
[4] Univ Witwatersrand, Johannesburg, South Africa
[5] AIDS Support Org TASO, Masaka, Uganda
[6] Wellcome Trust Res Labs, London, England
[7] Infect Dis Inst, Kampala, Uganda
[8] Minist Hlth, Kampala, Uganda
[9] London Sch Hyg & Trop Med, London WC1, England
来源
LANCET INFECTIOUS DISEASES | 2011年 / 11卷 / 12期
基金
英国医学研究理事会;
关键词
IMMUNODEFICIENCY-VIRUS-INFECTION; ACTIVE ANTIRETROVIRAL THERAPY; SYSTEMIC FUNGAL-INFECTIONS; EARLY MORTALITY; AMPHOTERICIN-B; MENINGITIS; PREVENTION; EPIDEMIOLOGY; SURVEILLANCE; ITRACONAZOLE;
D O I
10.1016/S1473-3099(11)70245-6
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Background Cryptococcal disease remains an important cause of morbidity and mortality in HIV-infected individuals in sub-Saharan Africa, despite the introduction of antiretroviral therapy. We studied fluconazole as primary prophylaxis against cryptococcal disease in patients awaiting or starting antiretroviral therapy in Uganda. Methods In this prospective, double-blind randomised controlled trial, we enrolled HIV-positive adults with CD4 counts less than 200 cells per mu L, cryptococcal antigen (CrAg)-negative, naive for antiretroviral therapy, and coming from five local AIDS organisations in Masaka district, Uganda. Enrolment took place between Sept 14, 2004, and Feb 1, 2008. Participants were randomly allocated to placebo or 200 mg fluconazole three times per week (1:1) in blocks of 40. Randomisation was done with ralloc procedure in Stata. Participants were reviewed after 4 weeks and referred for antiretroviral therapy, then seen every 8 weeks. Participants discontinued trial treatment when CD4 counts reached 200 cells per mu L (median 197 days). Primary endpoints were invasive cryptococcal disease and all-cause mortality. Secondary endpoints were time to first episode and incidence of oesophageal candidosis, time to first episode and incidence of oropharyngeal or vaginal candidosis, and time to first hospital admission or death. The primary safety endpoint was cessation of trial drug because of transaminase concentrations higher than five times the upper limit of normal (ULN), or other major adverse events. Analyses were done by intention to treat and included all participants enrolled in the trial. Participants and researchers were masked to group assignment. This trial is registered with controlled-trials.com, number ISRCTN 76481529. Results Of 1519 individuals enrolled, 760 participants received fluconazole and 759 received placebo. 19 developed cryptococcal disease, one in the fluconazole group and 18 in the placebo group (p=0.0001); adjusted HR (aHR) 18.7 (95% CI 2.5-140.7). One case of cryptococcal disease could be prevented by treating 44.6 patients with baseline CD4 counts lower than 200 cells per mu L. Fluconazole was effective against cryptococcal disease both before (aHR=11.0 [1.4-85.3]) and after start of antiretroviral therapy (no cases in fluconazole vs seven cases on placebo). Seven participants died from cryptococcal disease, none in the fluconazole group. All-cause mortality (n=189) did not differ between the two groups (p=0.46). Fluconazole reduced the time to first episode of oesophageal, and oropharyngeal and vaginal candidosis, as well as the incidence of all candidosis (p<0.0001), but had no effect on hospital admission or death. The frequency of elevated transaminases (>5xULN) was similar between groups (aHR=0.94 [0.65-1.35]). Conclusions Fluconazole was safe and effective as primary prophylaxis against cryptococcal disease, both before and during early antiretroviral treatment. Cryptococcal infection was less common than anticipated because of the rapid commencement of antiretroviral therapy and exclusion of those with positive CrAg. In patients with negative CrAg on screening, fluconazole prophylaxis can prevent cryptococcal disease while waiting for and in the early weeks of antiretroviral therapy, particularly in those with CD4 counts of less than 100 cells per mu L.
引用
收藏
页码:933 / 941
页数:9
相关论文
共 50 条
  • [1] A double-blind, placebo-controlled trial of testosterone therapy for HIV-positive men with hypogonadal symptoms
    Rabkin, JG
    Wagner, GJ
    Rabkin, R
    ARCHIVES OF GENERAL PSYCHIATRY, 2000, 57 (02) : 141 - 147
  • [2] Randomised, double-blind, placebo-controlled trial of EPs 7630 in adults with COPD
    Matthys, Heinrich
    Pliskevich, Dina A.
    Bondarchuk, Oleksandr M.
    Malek, Fathi A.
    Tribanek, Michael
    Kieser, Meinhard
    RESPIRATORY MEDICINE, 2013, 107 (05) : 691 - 701
  • [3] Montelukast for postinfectious cough in adults: a double-blind randomised placebo-controlled trial
    Wang, Kay
    Birring, Surinder S.
    Taylor, Kathryn
    Fry, Norman K.
    Hay, Alastair D.
    Moore, Michael
    Jin, Jing
    Perera, Rafael
    Farmer, Andrew
    Little, Paul
    Harrison, Timothy G.
    Mant, David
    Harnden, Anthony
    LANCET RESPIRATORY MEDICINE, 2014, 2 (01): : 35 - 43
  • [4] Adjunctive sertraline for HIV-associated cryptococcal meningitis: a randomised, placebo-controlled, double-blind phase 3 trial
    Rhein, Joshua
    Hullsiek, Kathy Huppler
    Tugume, Lillian
    Nuwagira, Edwin
    Mpoza, Edward
    Evans, Emily E.
    Kiggundu, Reuben
    Pastick, Katelyn A.
    Ssebambulidde, Kenneth
    Akampurira, Andrew
    Williams, Darlisha A.
    Bangdiwala, Ananta S.
    Abassi, Mahsa
    Musubire, Abdu K.
    Nicol, Melanie R.
    Muzoora, Conrad
    Meya, David B.
    Boulware, David R.
    Ndyetukira, Jane Francis
    Ahimbisibwe, Cynthia
    Kugonza, Florence
    Namuju, Carolyne
    Sadiq, Alisat
    Namudde, Alice
    Mwesigye, James
    Tadeo, Kiiza K.
    Kirumira, Paul
    Okirwoth, Michael
    Luggya, Tonny
    Kaboggoza, Julian
    Laker, Eva
    Atwine, Leo
    Muganzi, Davis
    Walukaga, Stewart
    Jawed, Bilal
    Merry, Matthew
    Stadelman, Anna
    Stephens, Nicole
    Flynn, Andrew G.
    Fujita, Ayako W.
    Kwizera, Richard
    Mukaremera, Liliane
    Lofgren, Sarah M.
    Cresswell, Fiona V.
    Morawski, Bozena M.
    Bahr, Nathan C.
    Nielsen, Kirsten
    LANCET INFECTIOUS DISEASES, 2019, 19 (08): : 843 - 851
  • [5] A multicentre, randomized, double-blind, placebo-controlled trial of primary cryptococcal meningitis prophylaxis in HIV-infected patients with severe immune deficiency
    Chetchotisakd, P
    Sungkanuparph, S
    Thinkhamrop, B
    Mootsikapun, P
    Boonyaprawit, P
    HIV MEDICINE, 2004, 5 (03) : 140 - 143
  • [6] A double-blind placebo-controlled trial of nabumetone in the prophylaxis of migraine
    Diamond, S
    Freitag, FG
    Diamond, ML
    Urban, GJ
    Pepper, BJ
    HEADACHE QUARTERLY-CURRENT TREATMENT AND RESEARCH, 1996, 7 (04): : 326 - 329
  • [7] A DOUBLE-BLIND PLACEBO-CONTROLLED TRIAL OF INDOBUFEN IN THE PROPHYLAXIS OF MIGRAINE
    CARRIERI, PB
    OREFICE, G
    SORGE, F
    ACTA NEUROLOGICA SCANDINAVICA, 1988, 77 (06): : 433 - 436
  • [8] CryptoDex: A randomised, double-blind, placebo-controlled phase III trial of adjunctive dexamethasone in HIV-infected adults with cryptococcal meningitis: study protocol for a randomised control trial
    Jeremy Day
    Darma Imran
    Ahmed Rizal Ganiem
    Natriana Tjahjani
    Retno Wahyuningsih
    Robiatul Adawiyah
    David Dance
    Mayfong Mayxay
    Paul Newton
    Rattanaphone Phetsouvanh
    Sayaphet Rattanavong
    Adrienne K Chan
    Robert Heyderman
    Joep J van Oosterhout
    Wirongrong Chierakul
    Nick Day
    Anatoli Kamali
    Freddie Kibengo
    Eugene Ruzagira
    Alastair Gray
    David G Lalloo
    Justin Beardsley
    Tran Quang Binh
    Tran Thi Hong Chau
    Nguyen Van Vinh Chau
    Ngo Thi Kim Cuc
    Jeremy Farrar
    Tran Tinh Hien
    Nguyen Van Kinh
    Laura Merson
    Lan Phuong
    Loc Truong Tho
    Pham Thanh Thuy
    Guy Thwaites
    Heiman Wertheim
    Marcel Wolbers
    Trials, 15
  • [9] CryptoDex: A randomised, double-blind, placebo-controlled phase III trial of adjunctive dexamethasone in HIV-infected adults with cryptococcal meningitis: study protocol for a randomised control trial
    Day, Jeremy
    Imran, Darma
    Ganiem, Ahmed Rizal
    Tjahjani, Natriana
    Wahyuningsih, Retno
    Adawiyah, Robiatul
    Dance, David
    Mayxay, Mayfong
    Newton, Paul
    Phetsouvanh, Rattanaphone
    Rattanavong, Sayaphet
    Chan, Adrienne K.
    Heyderman, Robert
    van Oosterhout, Joep J.
    Chierakul, Wirongrong
    Day, Nick
    Kamali, Anatoli
    Kibengo, Freddie
    Ruzagira, Eugene
    Gray, Alastair
    Lalloo, David G.
    Beardsley, Justin
    Tran Quang Binh
    Tran Thi Hong Chau
    Nguyen Van Vinh Chau
    Ngo Thi Kim Cuc
    Farrar, Jeremy
    Tran Tinh Hien
    Nguyen Van Kinh
    Merson, Laura
    Lan Phuong
    Loc Truong Tho
    Pham Thanh Thuy
    Thwaites, Guy
    Wertheim, Heiman
    Wolbers, Marcel
    TRIALS, 2014, 15
  • [10] Probiotic prophylaxis in predicted severe acute pancreatitis: a randomised, double-blind, placebo-controlled trial
    Besselink, Marc G. H.
    van Santvoort, Hjalmar C.
    Buskens, Erik
    Boermeester, Marja A.
    van Goor, Harry
    Timmerman, Harro M.
    Nieuwenhuijs, Vincent B.
    Bollen, Thomas L.
    van Ramshorst, Bert
    Witteman, Ben J. M.
    Rosman, Camiel
    Ploeg, Rutger J.
    Brink, Menno A.
    Schaapherder, Alexander F. M.
    Dejong, Cornelis H. C.
    Wahab, Peter J.
    van Laarhoven, Cees J. H. M.
    van der Harst, Erwin
    van Eijck, Casper H. J.
    Cuesta, Miguel A.
    Akkermans, Louis M. A.
    Gooszen, Hein G.
    LANCET, 2008, 371 (9613): : 651 - 659